Guardant Health, INC 8-K filings

Guardant Health reported a 44% year-over-year revenue increase to $335.0 million for the second quarter of 2026, driven by strong performance in Oncology and Screening, leading to an upward revision of full-year revenue guidance.

Guardant Health's annual meeting saw directors elected and auditor ratified, but advisory executive compensation vote failed.

Guardant Health reported a 48% year-over-year revenue increase to $301.7 million for Q1 2026, driven by strong oncology and screening performance, leading to an upward revision of full-year revenue guidance.

Guardant Health, Inc. announced the resignation of Chief Medical Officer Craig Eagle, M.D., effective May 8, 2026.

Guardant Health announced robust fourth quarter and full year 2025 financial results, driven by significant growth in oncology and screening revenue, alongside a positive 2026 outlook.

Guardant Health announced preliminary unaudited Q4 and full year 2025 results, showing significant revenue and test volume growth driven by oncology and screening.

Guardant Health successfully completed an upsized public offering of common stock and a private offering of 0% convertible senior notes due 2033, raising approximately $717.2 million in net proceeds for general corporate purposes, including potential repurchase of existing 2027 notes.

Guardant Health reported strong third-quarter 2025 financial results, with revenue up 39% and increased its full-year 2025 revenue guidance.

Guardant Health, Inc. announced it will host an Investor Day on September 24, 2025, to provide updates on operations, strategic priorities, and financial outlook.

Guardant Health, a precision oncology company, announced the appointment of Alex M. Azar II, former U.S. Secretary of Health and Human Services, to its Board of Directors.

Guardant Health reported robust second-quarter 2025 financial results, driven by significant growth across its oncology, screening, and biopharma segments, leading to an upward revision of its full-year 2025 revenue forecast.

Guardant Health, Inc. announced the results of its annual meeting held on June 18, 2025, where stockholders elected all director nominees, ratified Deloitte & Touche LLP as its independent auditor, and approved executive compensation on an advisory basis.

Guardant Health's Q1 2025 revenue increased by 21%, driven by growth across oncology, screening, and biopharma, leading to an increased full-year revenue guidance of $880 to $890 million.

Guardant Health extends its Redwood City facility lease through 2030 or 2031, with a total value of approximately $50 million.

Guardant Health announces a 31% increase in total revenue for 2024, driven by clinical oncology volume growth and product upgrades, and anticipates revenue between $850 and $860 million for 2025.

Guardant Health completed a private exchange agreement, issuing $600 million in new convertible notes due in 2031 to retire approximately $659.3 million of its 2027 notes.

Guardant Health will issue $600 million in new convertible notes due 2031 in exchange for $659.3 million of its 2027 notes, while also repurchasing shares.

Guardant Health reports preliminary unaudited results for Q4 and full year 2024, highlighting a 31% increase in full-year revenue.

Guardant Health reported strong third-quarter results, driven by increased clinical and biopharma test volumes and favorable reimbursement, leading to an increased revenue guidance for 2024.

Guardant Health has appointed Roberto Mignone, founder of Bridger Management, to its board of directors, effective October 21, 2024.

Guardant Health has entered into an agreement to sell up to $400 million of its common stock through an at-the-market offering program.

Guardant Health announced a 29% revenue increase in Q2 2024, driven by strong clinical and biopharma volume, and raised its full-year revenue guidance.

The FDA has approved Guardant Health's Shield blood test as a primary screening option for colorectal cancer in adults 45 and older, marking a significant advancement in non-invasive cancer detection.

Guardant Health has expanded its board of directors with the appointment of Dr. Manuel Hidalgo Medina, a renowned expert in oncology.

Guardant Health's annual meeting saw the election of all director nominees and the ratification of Deloitte & Touche LLP as the company's auditor, but an advisory vote on executive compensation failed to pass.

Guardant Health has updated its executive severance plan, increasing benefits for its Co-CEOs, particularly in the event of a change in control or termination.

An FDA advisory panel has strongly recommended the approval of Guardant Health's Shield blood test for colorectal cancer screening in average-risk adults aged 45 and older.

Guardant Health reported a strong first quarter with 31% revenue growth and increased its full-year revenue and free cash flow guidance.

Guardant Health has amended the compensation agreements for its co-CEOs, replacing cash bonuses with significant annual and long-term equity awards.

Guardant Health's full year 2023 revenue increased by 25%, driven by a 39% growth in clinical test volume, and the company anticipates revenue between $655 to $670 million for 2024.